New pill aims to slow kidney disease in IgA nephropathy patients
NCT ID NCT07606352
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include nausea, dizziness, and tiredness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Research Site
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Research Site
NOT_YET_RECRUITINGClayton, Victoria, 3168, Australia
-
Research Site
RECRUITINGSaint Albans, Victoria, 3021, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow kidney damage in IgA nephropathy?
- Can a gut metabolite shield the kidneys in IgA nephropathy?
- Can a new pill protect kidneys from IgA nephropathy?
- New pill aims to tame kidney disease in Long-Term trial
- New drug aims to protect kidneys in IgA nephropathy patients
- New drug shows promise for kidney disease in phase 2 trial